No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA

CONCLUSION: The findings of this study suggest that a single dose of intravenous TXA may be adequate to control excessive blood loss and reduce blood transfusion in simultaneous bilateral TKA. Despite its short half-life, TXA still appears to be effective in this demanding procedure without requiring prolonged plasma concentrations obtained from multiple doses. Additional high-quality studies are still needed to determine the most appropriate dosing regimen.LEVEL OF EVIDENCE: Level III, therapeutic study.PMID:35302971 | PMC:PMC8923576 | DOI:10.1097/CORR.0000000000002037

Source: Clinical Orthopaedics and Related Research - March 18, 2022 Category: Orthopaedics Authors: Jeffrey M Wilde Steven N Copp Kace A Ezzet Adam S Rosen Richard H Walker Julie C McCauley Audree S Evans William D Bugbee Source Type: research